DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19415575Curator's Comment: description was created based on several sources, including
https://www.accessdata.fda.gov/cdrh_docs/pdf9/P090031c.pdf | https://www.ncbi.nlm.nih.gov/pubmed/17773757 | https://www.ncbi.nlm.nih.gov/pubmed/10903951 | https://www.ncbi.nlm.nih.gov/pubmed/19415575 | https://www.ncbi.nlm.nih.gov/pubmed/10903951 | https://www.ncbi.nlm.nih.gov/pubmed/16049255
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19415575
Curator's Comment: description was created based on several sources, including
https://www.accessdata.fda.gov/cdrh_docs/pdf9/P090031c.pdf | https://www.ncbi.nlm.nih.gov/pubmed/17773757 | https://www.ncbi.nlm.nih.gov/pubmed/10903951 | https://www.ncbi.nlm.nih.gov/pubmed/19415575 | https://www.ncbi.nlm.nih.gov/pubmed/10903951 | https://www.ncbi.nlm.nih.gov/pubmed/16049255
Hyaluronic acid (HA) is a high molecular weight biopolysacharide, discovered in 1934, by Karl Meyer and his assistant, John Palmer in the vitreous of bovine eyes. Hyaluronic acid is a naturally occurring biopolymer, which has important biological functions in bacteria and higher animals including humans. It is found in most connective tissues and is particularly concentrated in synovial fluid, the vitreous fluid of the eye, umbilical cords and chicken combs. It is naturally synthesized by a class of integral membrane proteins called hyaluronan synthases, and degraded by a family of enzymes called hyaluronidases. Hyaluronan synthase enzymes synthesize large, linear polymers of the repeating disaccharide structure of hyaluronan by alternating addition of glucuronic acid and N-acetylglucosamine to the growing chain using their activated nucle¬otide sugars (UDP – glucuronic acid and UDP-N-acetlyglucosamine) as substrates. The number of repeat disaccharides in a completed hyaluronan molecule can reach 10 000 or more, a molecular mass of ~4 million daltons (each disaccharide is ~400 daltons). The average length of a disaccharide is ~1 nm. Thus, a hyaluronan molecule of 10 000 repeats could ex¬tend 10 μm if stretched from end to end, a length approximately equal to the diameter of a human erythrocyte. Although the predominant mechanism of HA is unknown, in vivo, in vitro, and clinical studies demonstrate various physiological effects of exogenous HA. Hyaluronic acid possesses a number of protective physiochemical functions that may provide some additional chondroprotective effects in vivo and may explain its longer term effects on articular cartilage. Hyaluronic acid can reduce nerve impulses and nerve sensitivity associated with pain. In experimental osteoarthritis, this glycosaminoglycan has protective effects on cartilage. Exogenous HA enhances chondrocyte HA and proteoglycan synthesis, reduces the production and activity of proinflammatory mediators and matrix metalloproteinases, and alters the behavior of immune cells. In addition to its function as a passive structural molecule, hyaluronan also acts as a signaling molecule by interacting with cell surface receptors and regulating cell proliferation, migration, and differentiation. Hyaluronan is essential for embryogenesis and is likely also important in tumorigenesis. HA plays several important organizational roles in the extracellular matrix (ECM) by binding with cells and other components through specific and nonspecific interactions. Hyaluronan-binding pro¬teins are constituents of the extracellular matrix, and stabilize its integrity. Hyaluronan receptors are involved in cellular signal transduction; one receptor family includes the binding proteins aggrecan, link protein, versican and neurocan and the receptors CD44, TSG6, GHAP and LYVE-1. The chondroprotective effects of hyaluronic acid, e.g., that it stimulates the production of tissue in¬hibitors of matrix metalloproteineses (TIMP-1) by chondrocytes, inhibits neutrophil-mediated cartilage degradation and attenuates IL-1 induced matrix de¬generation and chondrocyte cytotoxicity have been observed in vitro. Articular chondrocytes cultured in the presence of HA have a significantly greater rate of DNA proliferation and ex¬tracellular matrix production, compared with chon¬drocytes cultured without HA.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P98066 Gene ID: 7130.0 Gene Symbol: TNFAIP6 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10903951 |
0.5 µM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Monovisc Approved UseMONOVISC™ is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics (e.g., acetaminophen). Launch Date2014 |
Sample Use Guides
Monovisc™ (Hyaluronic acid, Hyaluronan) is injected into the knee joint and is administered as a single intra-articular injection. Each single intra-articular injection of Monovisc™ contains 88 mg of Hyaluronan.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16049255
Bovine articular chondrocytes were isolated and seeded into alginate constructs. The alginate gels were made to four different concentrations of hyaluronic acid: 0.1, 1.0, 2.0, and 3.0 mg/mL. The control specimens contained alginate that was free from hyaluronic acid. The alginate/chondrocyte/hyaluronic acid suspensions were then gently expressed through a 22-gauge needle attached to a 5 mL syringe into a 100 mm CaCl2 solution in a sterile Petri dish and each drop polymerised to form an alginate bead containing approximately 100 000 chondrocytes. Twenty minutes of incubation was allowed for further polymerisation. The newly-formed beads were then washed twice in EBSS to remove excess CaCl2. Five sets of beads containing hyaluronic acid at the four different concentrations, and a control set of beads containing chondrocytes without hyaluronic acid, were formed and were used for the culture experiments. Each set of alginate beads was then transferred into sterile 24-well culture plates, with eight randomly chosen beads placed in each well containing 1 mL of culture medium supplemented with hyaluronic acid at the same concentration as that in the respective alginate beads. The hydrogel constructs were cultured for a period of 14 days in the humidified atmosphere of a standard incubator at 37°C and 5% CO2. The culture medium was replaced by fresh culture medium every three days. Six replicates of eight alginate beads were removed randomly from each of the five cultures at 0, 3, 6, 9, and 14 days for analysis.
Substance Class |
Polymer
Created
by
admin
on
Edited
Sat Dec 16 09:15:01 GMT 2023
by
admin
on
Sat Dec 16 09:15:01 GMT 2023
|
Record UNII |
S270N0TRQY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28153
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
550716
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
WHO-ATC |
S01KA51
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
WHO-VATC |
QD03AX05
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
WHO-VATC |
QR01AX09
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
153501
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
WHO-VATC |
QS01KA01
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
WHO-ATC |
S01KA01
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
WHO-VATC |
QM09AX01
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
WHO-ATC |
R01AX09
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
WHO-ATC |
M09AX01
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
DSLD |
467 (Number of products:627)
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
WHO-ATC |
D03AX05
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
||
|
WHO-VATC |
QS01KA51
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m6066
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB14126MIG
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
S270N0TRQY
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
D006820
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
132153
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
27306
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
ALTERNATIVE | |||
|
5463
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
232-678-0
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
C549
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
62372
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
ALTERNATIVE | |||
|
9004-61-9
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
3957
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
9004-61-9
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
GENERIC (FAMILY) | |||
|
DB08818
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
100000092136
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
C049816
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
258347
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
ALTERNATIVE | |||
|
HYALURONAN
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110674
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
S270N0TRQY
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY | |||
|
16336
Created by
admin on Sat Dec 16 09:15:01 GMT 2023 , Edited by admin on Sat Dec 16 09:15:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|